铺子
发表于 2025-3-23 09:55:11
Perspectives in targeted therapy,ombination with methotrexate, use in moderate rather than severe disease, tight control as well as induration and maintenance regimes. Despite therapeutic advances with target therapies a number of unmet needs exist, including a low remission rate, cost and inadequate access as well as the lack of b
金丝雀
发表于 2025-3-23 15:30:37
Book 2009 inflammatory diseases. Anti-TNF treatment results in cli- cal benefit in a significant proportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients
黄瓜
发表于 2025-3-23 21:49:41
1422-7746 oportion of the patients, and it has provided proof of concept for the principle of targeted therapy. Despite the impressive disease-modifying effects of the TNF blockers, not all patients respond, and patients978-3-7643-8238-4Series ISSN 1422-7746 Series E-ISSN 2296-4525
jettison
发表于 2025-3-23 23:52:35
http://reply.papertrans.cn/67/6659/665854/665854_14.png
palpitate
发表于 2025-3-24 03:58:05
http://reply.papertrans.cn/67/6659/665854/665854_15.png
Albumin
发表于 2025-3-24 08:58:03
http://reply.papertrans.cn/67/6659/665854/665854_16.png
chapel
发表于 2025-3-24 10:52:38
http://reply.papertrans.cn/67/6659/665854/665854_17.png
Entreaty
发表于 2025-3-24 17:04:50
http://reply.papertrans.cn/67/6659/665854/665854_18.png
有特色
发表于 2025-3-24 20:36:27
B cell targets in rheumatoid arthritis,atients with RA using the first licensed agent, rituximab. Recent research has focused on enhancing efficacy using other targets to inhibit B cell function, including other B cell-depleting antibodies and cytokines critical to B cell function. The rationale for new B cell targets is discussed, as we
Isolate
发表于 2025-3-25 00:13:09
Co-stimulatory pathways in the therapy of rheumatoid arthritis, cell populations have not been clinically successful, largely due to the toxicity associated with nonspecific T cell depletion. An alternative approach involves targeting T cell activation, a process that requires two distinct signals. In addition to the cognate interaction between the T cell recep